AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01158885
Drug: Intrathecal (IT) Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age
Trial: NCT04818931
Drug: Cefazolin Injection
RxNorm normalized name: cefazolin Injection
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefazolin 2 g or clindamycin 900 mg in case of penicillin allergy
Trial: NCT01392638
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
Trial: NCT01157585
Drug: paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 8 week prospective study
Trial: NCT00197613
Drug: (A) zidovudine, lamivudine and nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00197613
Drug: (B) zidovudine, lamivudine and efavirenz
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00408785
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
Trial: NCT00408785
Drug: sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium chloride 0.9 mg
Trial: NCT00197613
Drug: (C) zidovudine, didanosine, and nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03237416
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
Trial: NCT03237416
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
Trial: NCT03237416
Drug: BAY1841788 (darolutamide)
RxNorm normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
Trial: NCT03724942
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
Trial: NCT03859869
Drug: Pancrelipase
RxNorm normalized name: pancrelipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrelipase is administered orally as capsules with a meal or snack
Trial: NCT00558506
Drug: abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenously 750mg (in patients with weight of 60- 100kg)
Trial: NCT03640949
Drug: Vasopressin, Arginine
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)
Trial: NCT03640949
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone once
Trial: NCT03640949
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo
Trial: NCT02220660
Drug: BI 1744 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02220660
Drug: BI 54903 XX
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02220660
Drug: BI 1744 CL + BI 54903 XX FDC
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03717506
Drug: GDC 268 Lotion
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC 268 is a topical lotion
Trial: NCT03717506
Drug: GDC Vehicle Lotion
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
Trial: NCT04092205
Drug: Emeramide
RxNorm normalized name: Emeramide
DrugBank: Emeramide (DB12192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipophilic, membrane passing Metal chelator and anti oxidant
Trial: NCT02778659
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Trial: NCT04325685
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
Trial: NCT04325685
Drug: Antiseptic Solution
RxNorm normalized name: ANTISEPTIC SOLUTION
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
Trial: NCT02845297
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous pembrolizumab
Trial: NCT02845297
Drug: Azacitadine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous or subcutaneous
Trial: NCT03164486
Drug: 18F-αvβ6-BP
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
Trial: NCT00909025
Drug: Claudiximab
RxNorm normalized name: Claudiximab
DrugBank: Zolbetuximab (DB15118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks.
Trial: NCT03582722
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.
Trial: NCT01678794
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
Trial: NCT02772601
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02772601
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02772601
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02772601
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02772601
Drug: Risankizumab
RxNorm normalized name: RISANKIZUMAB
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03647423
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: injection
Trial: NCT03086044
Drug: Sofosbuvir/velpatasvir
RxNorm normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 weeks of treatment beginning on the day of transplant
Trial: NCT00519558
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03647423
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection
Trial: NCT01733420
Drug: White MTA pulpotomy
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03121313
Drug: tegafur-uracil
RxNorm normalized name: Tegafur-uracil
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01288573
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 μg/kg subcutaneous (SC) injection
Trial: NCT01288573
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 240 μg/kg subcutaneous (SC) injection
Trial: NCT01288573
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 320 μg/kg subcutaneous (SC) injection
Trial: NCT00179621
Drug: Lenalidomide 5 mg
RxNorm normalized name: lenalidomide 5 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 5 mg daily 28/28 days
Trial: NCT00179621
Drug: Lenalidomide 10 mg
RxNorm normalized name: lenalidomide 10 MG
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 10 mg daily 21/28 days
Trial: NCT01866540
Drug: FLUENZ
RxNorm normalized name: INFLUENZA
DrugBank: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (DB10076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: live attenuated influenza vaccine
Trial: NCT00291616
Drug: Pegylated Interferon-alpha2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 microgram s.c. injection weekly
Trial: NCT03342027
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: medication for smoking cessation
Trial: NCT02160756
Drug: JNJ-56021927 Softgel Capsule
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
Trial: NCT02160756
Drug: JNJ-56021927 Tablet Formulation 1
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
Trial: NCT02160756
Drug: JNJ-56021927 Tablet Formulation 2
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
Trial: NCT02160756
Drug: JNJ-56021927 Tablet Formulation 3
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
Trial: NCT02357524
Drug: Oritavancin
RxNorm normalized name: Oritavancin
DrugBank: Oritavancin (DB04911)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02376049
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02376049
Drug: Betamethasone dipropionate cream
RxNorm normalized name: Betamethasone Dipropionate Cream
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02376049
Drug: Clobetasol propionate cream
RxNorm normalized name: Clobetasol Propionate Cream
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02646332
Drug: dexlan+clarith+amox+metro
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
Trial: NCT00984256
Drug: Atovaquone Proguanil
RxNorm normalized name: atovaquone / proguanil
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
Trial: NCT01083615
Drug: custirsen sodium
RxNorm normalized name: Custirsen
DrugBank: Custirsen (DB05487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An antisense oligonucleotide that blocks production of clusterin
Trial: NCT01083615
Drug: isotonic, 0.9% sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for custirsen sodium
Trial: NCT02237417
Drug: IM aripiprazole once monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
Trial: NCT01083615
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02025686
Drug: Hyperbaric Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
Trial: NCT01908426
Drug: Cabozantinib tablets
RxNorm normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01102335
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: anti-HBV drug
Trial: NCT01083615
Drug: cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01083615
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01853826
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive afatinib once daily
Trial: NCT01279434
Drug: Vitamin E plus Pentoxiphyllin
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
Trial: NCT01279434
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 mg BD daily for 12 months
Trial: NCT00805350
Drug: Eplivanserin
RxNorm normalized name: Eplivanserin
DrugBank: Eplivanserin (DB12177)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 5 mg tablet once a day
Trial: NCT01273766
Drug: deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT01033981
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment for mRCC as indication approved and physician criterium
Trial: NCT00262860
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00262860
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05974241
Drug: Methylphenidate, aripiprazole, and combination
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks). The primary outcome was improvement of irritability as measured by Aberrant Behavior Checklist-irritability subscale (ABC-I). During the first step, the subjects received pharmacological treatment of methylphenidate with flexible dosage for 4 weeks. Those subjects who had suboptimal response to methylphenidate (reduction of ABC-I score \< 25%) entered the second step and the medication was switched to aripiprazole. After 4 weeks of treatment, those whose ABC-I scores reduced \< 25% entered the third step and received the treatment of combination of methylphenidate and aripiprazole for two weeks (3rd step).
Trial: NCT03721068
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m\^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
Trial: NCT04169763
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04169763
Drug: Nelfinavir
RxNorm normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00445549
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg daily dose, 28 day cycle
Trial: NCT00379535
Drug: potassium iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: per os
Trial: NCT03447379
Drug: P2Y12 antagonist monotherapy
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
Trial: NCT03447379
Drug: Aspirin plus P2Y12 antagonist
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
Trial: NCT00489996
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00489996
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02669953
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00575185
Drug: Valomaciclovir
RxNorm normalized name: Valomaciclovir
DrugBank: Valomaciclovir (DB06575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams orally of valomaciclovir (2 grams BID) for 21 days.
Trial: NCT00246519
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
Trial: NCT00246519
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atenolol 50 mg, then 100 mg if BP \< 120/70, then add HCTZ 12.5 mg if BP \< 120/70, then HCTZ 25 mg if BP \< 120/70
Trial: NCT02172430
Drug: Tiotropium powder inhalation capsules
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder inhalation via the HandiHaler® once daily
Trial: NCT00001483
Drug: sertraline (Zoloft)
RxNorm normalized name: sertraline Oral Solution [Zoloft]
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001483
Drug: venlafaxine (Effexor)
RxNorm normalized name: venlafaxine Oral Tablet [Effexor]
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03056209
Drug: KL1333 25 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 25 mg 1 tab
Trial: NCT03056209
Drug: KL1333 50 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 25 mg 2 tabs
Trial: NCT03056209
Drug: KL1333 100 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 100 mg 1 tab
Trial: NCT03056209
Drug: KL1333 200 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 100 mg 2 tabs
Trial: NCT03056209
Drug: KL1333 400 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 100 mg 4 tabs
Trial: NCT03056209
Drug: KL1333 600 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 100 mg 6 tabs
Trial: NCT03056209
Drug: KL1333 800 mg
RxNorm normalized name: KL1333
DrugBank: KL1333 (DB17622)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration, single dose, 100 mg 8 tabs